



Neoadjuvant Chemotherapy - A New Challenge In Treatment Of Ovarian Cancer

Sadiqul Alam^{1*}, Abu Saleh Nizam Uddin Siddik¹, Ranadeep Borgohain²,
Priyakshi Chutia², Monami Rajiung³, Md Ariful Islam⁴

1. Department of Pharmacy, Tripura University (A Central University)

Suryamaninagar, Agartala, Tripura (W)-799022, India

2. Girjananda Chowdhury Institute of Pharmaceutical Science

Azara, Kamrup (M) -791017, Assam, India

3. NEF College of Pharmaceutical Education & Research

Nagaon-782001, Assam, India

4. Department of Pharmaceutical Sciences, Dibrugarh University

Dibrugarh-786004, Assam, India

*Corresponding author: email-sadiqul2015du@gmail.com

ABSTRACT

As per literature survey reveals that ovarian cancer is the most lethal gynecologic malignancy in females all over the world. In majority of patients who suffering from ovarian cancer clinical complete remissions are obtained through combinations of cytoreductive surgery and chemotherapy. This review represents an overview of the origin of ovarian cancer, history of chemotherapeutic regimens and also focused on chemotherapeutic agents which are useful in the treatment of ovarian cancer. Taxanes are most promising drug used in neoadjuvant chemotherapy. This review adds better advances in medical field may be based on the better understanding of drugs regimens and better control of cost in routine practice which opens the new doors for neoadjuvant chemotherapy which proves a better option in ovarian cancer treatment.

KEYWORDS: Neoadjuvant chemotherapy, ovarian cancer, drugs regimens, anti-tumor agents.

Received 02 August, 2021; Revised: 14 August, 2021; Accepted 16 August, 2021 © The author(s) 2021. Published with open access at www.questjournals.org

I. INTRODUCTION:

Cancer is a major public health problem in the United States, India and many other parts of the world. Currently, one in four deaths in the United States is due to cancer. (Table 1) has been shows the expected number of deaths from ovarian cancer projected for 2011 in the US [1].

Table: 1 Estimated New Cancer Cases and Deaths by Sex, United States, 2011

Sites	ESTIMATED NEW CASES		ESTIMATED DEATHS	
	Total deaths	FEMALE	Total deaths	FEMALE
Ovarian Cancer	21990	21990	15460	15460

An ovarian cancer is the most lethal gynecologic malignancy in the women. The origin and pathogenesis of epithelial ovarian cancer have long been investigated but still poorly understood. Studies have shown that epithelial ovarian cancer is not a single disease but is composed of diverse group of tumors that can be classified based on distinctive morphologic and molecular genetics features. Treatment of ovarian cancer is based on the combination of cytoreductive surgery and combination chemotherapy using taxane and platinum [2][3]. Still primary cytoreductive surgery followed by platinum and paclitaxel based chemotherapy is currently standard regimen for advanced ovarian cancer [4][5].

Table 2: Origin of Ovarian Cancer

Origin of Ovarian carcinoma cancer [6]			
Theories	Serous	Endometrioid/ Clear	Mucinous/ Brenner
Traditional	Mesothelium	Mesothelium	Mesothelium
Recent	Fimbria	Endometrial tissue	Tubal-mesothelial junction

Ovarian cancer is one of the most sensitive of all solid tumors to antineoplastic chemotherapy, and responses are expected in over 80% of women who receive standard platinum and paclitaxel based treatment [7]. Despite this fact; the majority of women with advanced ovarian cancer will ultimately relapse and develop drug-resistant disease. Treatment of epithelial ovarian cancer is based on the combination of surgery and chemotherapy [8][9]. Over the last few decades; surgical tumor debulking followed by platinum-based chemotherapy is the well recognized treatment for ovarian cancer. Although response rates and complete in disease are greater than 80% and 40-60% respectively. After treatment with paclitaxel and carboplatin most patients free survival up to 18 months [10].

While the focus of this manuscript is systemic or regional chemotherapy, selected patients may benefit from secondary cytoreductive surgery, in any discussion of second-line ovarian cancer therapy. Clinicians and patients can benefit from a shared understanding of basic treatment goals [11].

Now-a-days; patients who progress stable disease during first-line treatment within one month are considered to be „platinum-refractory“. Patients who respond to primary treatment and relapse within six months are considered to be „platinum-resistant“; and patients who relapse more than six months after completion of therapy are considered to be „platinum-sensitive“ [12].

Literature survey reveals that the longer platinum free interval (PFI) increases the chances for a benefit by platinum re-challenge. This has been reported for PFI longer than 12 months and who are relapsing 6-12 months classified as „partially sensitive“ [13] (Table 3).

Table 3: Association of Platinum Sensitivity and PFI

Association of Platinum Sensitivity and PFI [6]				
Platinum Sensitivity	Resistant		Sensitive	
	Refractory	Resistant	Partial Sensitive	Sensitive
PFI	During Chemotherapy	<06 months	06-12 months	>12 months

II. HISTORY OF CHEMOTHERAPY REGIMENS

Over the years; experts and research groups have explored different combinations of drugs in order to improve the prognosis of ovarian cancer. In 1976, the report by Witshaw and Kroner on the efficacy of cisplatin in treatment produced the modern era of combination chemotherapy. In early 1990 a new turning point in the treatment of ovarian cancer was related to discovery of paclitaxel. By comparing cisplatin/paclitaxel with cisplatin/cyclophosphamide, shown extra benefit when cyclophosphamide was replaced by paclitaxel. The carboplatin-paclitaxel combination is now considered universal regimen in treatment of ovarian cancer [14-16].

III. OVERVIEW OF ANTI-TUMOR AGENTS FOR OVARIAN CANCER THERAPY

3.1 Paclitaxel

Paclitaxel has been established as an important initial component of ovarian cancer chemotherapy [8], and should be considered in the management of patients with recurrence. As a component of initial platinum-based chemotherapy, paclitaxel is currently administered as either a 3-h (175 mg/m²) or 24-h (135 mg/m²) intravenous infusion. Phase III randomized trials in patients with recurrent disease have evaluated dose intensity (135 versus 175 and 175 versus 250 mg/m²) and infusion duration (3 versus 24 h) without a clear advantage to either higher doses or prolonged infusion[17][18].

3.2 Docetaxel

Docetaxel has been examined in several clinical trials for management of platinum-resistant ovarian cancer, with an objective response rate of approximately 20% to 35% being documented in this clinical setting [19-21]. This level of activity is comparable to that of paclitaxel observed in a similar patient population. The dose of single agent docetaxel in these studies has been 100 mg/m², delivered on an every-three-week schedule. It is not known if a lower dose regimen (e.g., 60 or 80 mg/m²) might result in a similar response rate with reduced toxicity. Preliminary data suggest that some patients with paclitaxel resistance may respond to subsequent therapy with Docetaxel [22].

3.3 Tamoxifen

Several clinical trials have been documented that tamoxifen is an active antineoplastic agent in platinum-resistant ovarian cancer, with an objective response rate of approximately 15% [23-26]. The major

advantage of tamoxifen in this clinical setting is the highly favorable toxicity profile for the agent, certainly compared to cytotoxic chemotherapy. As a result, tamoxifen may be considered the “treatment of choice” in several specific circumstances in the second-line setting for patients with ovarian cancer

3.4 Gemcitabine

Gemcitabine, recently approved by the FDA for treatment of pancreatic cancer, has been demonstrated to be an active second-line agent in ovarian cancer. Several phase II trials have revealed a 15% to 20% response rate in this clinical setting [27][28] although minimal activity was apparent when evaluated as front-line therapy in poor prognosis patients with advanced disease[29]. Because of the ability of gemcitabine to inhibit DNA repair, combinations with cisplatin and carboplatin are under development [30-32].

3.5 Ifosfamide

Several clinical trials have demonstrated ifosfamide to be an active agent in ovarian cancer patients after initial platinum-based therapy (10%-20% objective response rate) [33-35].

IV. CONCLUSION

Neoadjuvant chemotherapy of ovarian cancer continues to evolve as new agents with diverse mechanism of action. In view of the chronic nature of recurrent ovarian cancer, the achievement of stable disease with maintenance of performance status is an acceptable goal for many patients. This review covers better advances in medical field may be based on the better understanding of drugs regimen and better control of cost in routine practice which opens the new doors for neoadjuvant chemotherapy which proves a better option in ovarian cancer treatment.

REFERENCES

- [1]. Siegel R, Ward E, Brawley O, Jemal A: The Impact of Eliminating Socioeconomic and Racial Disparities on Premature Cancer Deaths. *Cancer Statistics* 2011; 212-36.
- [2]. Kurman RJ, Shih Ie M: The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. *Am. J Surg Pathol.* 2010; Association of Platinum Sensitivity and PFI 34: 433-43.
- [3]. Yutaka Ueda, T. Enomoto, *et al.* Therapeutic strategies in epithelial ovarian cancer. *Journal of Experimental & Clinical Cancer Research* 2012; 31:14. Doi: 10.1186/1756-9966-31-14.
- [4]. Thingpen T, The if and when of surgical debulking for ovarian cancer. *N. Engl J Med* 2004; 354 (24): 2544-46.
- [5]. Sharma S, *et al.* Neoadjuvant chemotherapy in advanced epithelial ovarian cancer: A retrospective study. *Indian Journal of Medical & Paediatric Oncology* 2007; 28:7-13.
- [6]. Kim *et al.* *Journal of experimental & clinical cancer research* 2012, 31: 14. doi: 10.1186/1756-9966-31-14.
- [7]. Cannistra SA, Cancer of the ovary. *N Engl J Med* 1993; 329:1550-59.
- [8]. McGuire WP, Hoskins WJ, Brady MF *et al.* Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. *N Engl J Med* 1996; 334:1-6.
- [9]. Bookman MA, McGuire WP III, Kilpatrick D *et al.* Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. *J Clin. Oncol.* 1996; 14:1895-1902.
- [10]. Rubin SC, Randall TC, *et al.* Ten year follows up of ovarian cancer patients after second look laparotomy with negative findings. *Obstet Gynecol* 1999; 93: 21-24.
- [11]. M. Markman, M. A. Bookman Second line treatment of ovarian cancer. *The oncologist* 2000; 5: 26-35. doi: 10.1634/theoncologist.5-1-26.
- [12]. Markman M, Reichman B, Hakes T, *et al.* Responses to second line cisplatin-based intraperitoneal therapy in ovarian cancer: influence of a prior response to intravenous cisplatin. *J Clin Oncol* 1991; 9:1801-05.
- [13]. Pisano C, Bruni GS, Facchini G, *et al.* Treatment of recurrent epithelial ovarian cancer. *Ther Clin Risk Manag* 2009; 5:421-26.
- [14]. McGuire WP, Ozols RF, Chemotherapy of advanced ovarian cancer. *Semin Oncol.* 1998; 25: 340-48.
- [15]. Piccart MJ, *et al.* Randomized intergroup trial cisplatin paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three year results. *J Natl Cancer Inst.* 2000; 92: 699-708.
- [16]. Muggia FM, Braly PS, Brady MF, *et al.* Phase III randomized study of 1 cisplatin versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. *J Clin Oncol.* 2000; 18: 106-115.
- [17]. Eisenhauer EA, Ten Bokkel Huinink WW, Swenerton KD *et al.* European-Canadian randomized trial of paclitaxel in relapsed ovarian cancer: high-dose versus low-dose and long versus short infusion. *J Clin Oncol.* 1994; 12:2654-66.
- [18]. Omura GA, Brady MF, Delmore JE *et al.* A randomized trial of paclitaxel (T) at 2 dose levels and filgrastim (G; G-CSF) at 2 doses in platinum (P) pretreated epithelial ovarian cancer (OVCA): a Gynecologic Oncology Group, SWOG, NCCTG and ECOG Study. *Proc Annu Meet Am Soc Clin Oncol.* 1996; 15:A755.
- [19]. Francis P, Schneider J, Hann L *et al.* Phase II trial of docetaxel in patients with platinum-refractory advanced ovarian cancer. *J Clin Oncol.* 1994; 12:2301-08.
- [20]. Kaye SB, Piccart M, Aapro M *et al.* Docetaxel in advanced ovarian cancer: preliminary results from three phase II trials. *Eur J Cancer* 1995; 31A (suppl 4):S14-S17.
- [21]. Piccart MJ, Gore M, ten Bokkel Huinink W *et al.* Docetaxel: an active new drug for treatment of advanced epithelial ovarian cancer. *J Natl Cancer Inst* 1995; 87:676-81.
- [22]. Kavanagh JJ, Winn R, Steger M *et al.* Docetaxel for patients with ovarian cancer refractory to paclitaxel, an update. *Proc Annu Meet Am Soc Clin Oncol* 1999; 18:A1423.
- [23]. Hatch KD, Beecham JB, Blessing JA *et al.* Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. *Cancer* 1991; 68:269-71.
- [24]. Markman M, Iseminger KA, Hatch KD *et al.* Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group ancillary report. *Gynecol Oncol.* 1996; 62:4-6.

- [25]. Ahlgren JD, Ellison NM, Gottlieb RJ *et al.* Hormonal palliation of chemoresistant ovarian cancer: three consecutive phase II trials of the Mid-Atlantic Oncology Program. *J Clin Oncol.* 1993; 11:1957-68.
- [26]. Williams CJ. Tamoxifen in relapsed ovarian cancer: a systematic review. *Int. J Gynecol Cancer* 1998; 8:89-94.
- [27]. Lund B, Hansen OP, Theilade K *et al.* Phase II study of gemcitabine (2',2'-difluorodeoxycytidine) in previously treated ovarian cancer patients. *Cancer Inst.* 1994; 86:1530-33.
- [28]. Shapiro JD, Millward MJ, Rischin D *et al.* Activity of gemcitabine in patients with advanced ovarian cancer: responses seen following platinum and paclitaxel. *Gynecol Oncol.*1996; 63:89-93.
- [29]. Underhill C, Parnis FX, Highley M *et al.* A phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer (EOC). *Proc Annu Meet Am Soc Clin Oncol* 1996; 15:A795.
- [30]. Peters GJ, Bergman AM, Ruiz van Haperen VW *et al.* Interaction between cisplatin and gemcitabine in vitro and in-vivo. *Semin Oncol.* 1995; 22(suppl 11):72-79.
- [31]. Pedersen AG. Phase I studies of gemcitabine combined with carboplatin or paclitaxel. *Semin Oncol.* 1997; 24(suppl 7):64-68.
- [32]. Bauknecht T, Grieshaber C, Breitbach G-P *et al.* Gemcitabine (GEM) in combination with cisplatin (CP) in previously untreated patients" ≥ 60 years with FIGO stage IIIC or IV epithelial ovarian cancer: a phase II study: preliminary results. *Proc Annu Meet Am Soc Clin Oncol* 1998; 17:A1376.
- [33]. Sutton GP, Blessing JA, Homesley HD *et al.* Phase II trial of ifosfamide and mesna in advanced ovarian carcinoma: a Gynecologic Oncology Group study. *J Clin Oncol.* 1989; 7:1672-76.
- [34]. Sorensen P, Pfeiffer P, Bertelsen K, A phase 2 trial of ifosfamide/mesna as salvage therapy in patients with ovarian cancer refractory to or relapsing after prior platinum-containing chemotherapy. *Gynecol Oncol.* 1995; 56:75-78.
- [35]. Markman M, Hakes T, Reichman B *et al.* Ifosfamide and mesna in previously treated advanced epithelial ovarian cancer: activity in platinum resistant disease. *J Clin Oncol.* 1991; 10:243-48